论文部分内容阅读
Objective:The mitomycin C and cisplatin combination was investigated in patients with advanced breast cancer who had been exposed to anthracyclines,vinorelbine and taxanes.Methods:Three-weekly regimen consisted of mitomycin,6 mg/m2 administered intravenously on day 1,and cisplatin,25 mg/m2 intravenously on day 1-3.Results:Thirty-eight patients aged 25-75 years(median,46 years)were treated with an overall response rate of 31.6%.The median time to progression(TTP)was 4.0 months.Median TTP for 12 patients with a complete or partial response was 9.0 months,while stable disease and progression of disease 4.0 months,P=0.002.Grade 3/4 side effects of neutropenia,thrombocytopenia and nausea/vomit-ing were documented in 4(10.5%),4(10.5%)and 3(7.9%)patients,respectively.The median overall survival was 13+ months.Conclusion:Mitomycin C/cisplatin doublet showed antitumor activity for anthracycline-,vinorelbine-and taxane-resistant breast cancer comparable to other regimens.This well-tolerated regimen provides an affordable option for patients in China.
Objective: The mitomycin C and cisplatin combination was investigated in patients with advanced breast cancer who had been exposed to anthracyclines, vinorelbine and taxanes.Methods: Three-weekly regimen consisted of mitomycin, 6 mg / m2 administered intravenously on day 1, and cisplatin, 25 mg / m2 intravenously on day 1-3. Results: Thirty-eight patients aged 25-75 years (median, 46 years) were treated with an overall response rate of 31.6%. The median time to progression (TTP) was 4.0 months . Median TTP for 12 patients with a complete or partial response was 9.0 months, while stable disease and progression of disease 4.0 months, P = 0.002.Grade 3/4 side effects of neutropenia, thrombocytopenia and nausea / vomit-ing were recorded in 4 (10.5%) and 3 (7.9%) patients, respectively.The median overall survival was 13+ months. Conclusions: Mitomycin C / cisplatin doublet showed antitumor activity for anthracycline-, vinorelbine-and taxane-resistant breast cancer comparable to other regimens. This well-tolerated regi men provides an affordable option for patients in China.